Cambrex High Point passes FDA PMDA TGA inspections
Analysis based on 10 articles · First reported Jul 20, 2026 · Last updated Aug 25, 2026
The successful completion of regulatory inspections at Cambrex's High Point facility enhances its commercial manufacturing capabilities, potentially attracting new clients and strengthening its competitive position in the CDMO market. This positive development may modestly improve investor sentiment toward Cambrex, though the company is privately held and not publicly traded.
Cambrex, a global contract development and manufacturing organization (CDMO), announced on August 25, 2026, that its High Point, North Carolina facility successfully completed Pre-Approval Inspections (PAIs) conducted by the U.S. United States — Food and Drug Administration (FDA), Japan's Japan — Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Australia — Therapeutic Goods Administration (TGA). The completion of these inspections enables the High Point site to manufacture approved active pharmaceutical ingredients (APIs) for the United States, Japan, and Australia, establishing it as the newest commercial manufacturing site within Cambrex's global network. This milestone follows a $38 million expansion of the facility completed in 2023, which added analytical and chemical development laboratories, clinical manufacturing suites, and commercial manufacturing operations with reactors up to 2,000 liters. The site is designed to support lower-volume commercial products, including orphan drugs, precision medicines, and other specialized therapies for smaller patient populations. Cambrex CEO Thomas Loewald highlighted the facility's purpose-built design to meet the industry's growing need for smaller-scale commercial manufacturing capacity. The successful inspections demonstrate the strength of Cambrex's quality systems and expand its ability to support customer programs throughout the product lifecycle.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard